January 9, 2024 05:30 AM ESTUpdated 09:54 AM
Financing
China
Pharma

RTW, Bay­er back Cy­to­ki­net­ics-al­lied Ji Xing Phar­ma­ceu­ti­cals with $162M: #JPM24

Kyle LaHucik

Senior Reporter

SAN FRAN­CIS­CO — RTW In­vest­ments is once again pro­vid­ing fund­ing to Ji Xing Phar­ma­ceu­ti­cals, the Shang­hai-based biotech it in­cu­bat­ed in 2019, with $127 mil­lion along­side a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times